Hologic (WBO:HOLX) Change In Receivables : €5 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Hologic Change In Receivables?

Hologic's change in receivables for the quarter that ended in Dec. 2023 was €-35 Mil. It means Hologic's Accounts Receivable increased by €35 Mil from Sep. 2023 to Dec. 2023 .

Hologic's change in receivables for the fiscal year that ended in Sep. 2023 was €-1 Mil. It means Hologic's Accounts Receivable increased by €1 Mil from Sep. 2022 to Sep. 2023 .

Hologic's Accounts Receivable for the quarter that ended in Dec. 2023 was €615 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hologic's Days Sales Outstanding for the three months ended in Dec. 2023 was 60.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hologic's liquidation value for the three months ended in Dec. 2023 was €-975 Mil.

Hologic Change In Receivables Historical Data

The historical data trend for Hologic's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Change In Receivables Chart

Hologic Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

-69.46

-362.61

94.27

275.02

-1.41

Hologic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-42.48	-34.37	28.43	46.38	-35.03

Hologic Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €5 Mil.

Hologic (WBO:HOLX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hologic's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	615.215	/	929.013	*	91
=	60.43

2. In Ben Graham's calculation of liquidation value, Hologic's accounts receivable are only considered to be worth 75% of book value:

Hologic's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1771.736	-	3498.997	+	0.75 * 615.215	+	0.5 * 581.011
=	-975

Hologic Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hologic's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hologic (WBO:HOLX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (WBO:HOLX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

HOLX:USA HOLX:Mexico HO1:Germany

Address

250 Campus Drive, Marlborough, MA, USA, 01752

Website

http://www.hologic.com

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.